Accéder au contenu
Merck

Antidepressant effects of citalopram on treatment of alopecia areata in patients with major depressive disorder.

The Journal of dermatological treatment (2013-01-24)
Hossein Abedini, Susan Farshi, Arash Mirabzadeh, Saeed Keshavarz
RÉSUMÉ

The authors sought to determine whether antidepressant therapy could enhance the efficacy of dermatological treatment in alopecia areata patients who suffer from major depressive disorder. Sixty patients were enrolled in the study. Thirty patients with alopecia who were diagnosed with major depressive disorder received 20 mg/day citalopram and 5 mg/mL triamcinolone injection every 4 weeks, up to six injections, and 30 patients received only triamcinolone injection each month for 6 months using a simple random method. The mean diameter of the alopecic patches in the triamcinolone injection only group as against the combined treatment group (psychiatric [citalopram] plus dermatologic treatment) before treatment was 2.7 ± 0.7 (mean ± SD) and 2.5 ± 1.8, respectively, with no statistically significant differences (Mann-Whitney, p = 0.08). After 6 months of therapy, the mean diameter of patches reached 1.6 ± 1 and 0.54 ± 0.97 in the triamcinolone injection only group and the combined treatment groups, respectively (Mann-Whitney, p < 0.0001). The results of this study showed that antidepressant treatment might help in improving alopecia areata in patients with major depressive disorder.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Triamcinolone
Triamcinolone, European Pharmacopoeia (EP) Reference Standard